相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017-2018), and on clonal distribution of MRSA
Eleonora Riccobono et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2022)
Comparative Analysis of Dalbavancin versus Other Antimicrobial Options for Gram-Positive Cocci Infections: Effectiveness, Hospital Stay and Mortality
Mar de Pablo-Miro et al.
ANTIBIOTICS-BASEL (2021)
Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study)
Francesca Bai et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2020)
Dalbavancin Reduces Hospital Stay and Improves Productivity for Patients with Acute Bacterial Skin and Skin Structure Infections: The ENHANCE Trial
Matthew W. McCarthy et al.
INFECTIOUS DISEASES AND THERAPY (2020)
Current Treatment Options for Acute Skin and Skin-structure Infections
Yoav Golan
CLINICAL INFECTIOUS DISEASES (2019)
Early discharge criteria in patients with acute bacterial skin and skin structure infections in a large tertiary-care teaching hospital in Florence, Italy
Filippo Lagi et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2019)
Dalbavancin use in an academic medical centre and associated cost savings
Amber C. Streifel et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Microbiology of acute bacterial skin and skin-structure infections in Greece: A proposed clinical prediction score for the causative pathogen
Christos Nodaras et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update
Silvano Esposito et al.
JOURNAL OF CHEMOTHERAPY (2017)
Landmark prediction of nosocomial infection risk to disentangle short- and long-stay patients
M. Wolkewitz et al.
JOURNAL OF HOSPITAL INFECTION (2017)
A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection
Michael W. Dunne et al.
CLINICAL INFECTIOUS DISEASES (2016)
Relationship between Adherence to Oral Antibiotics and Postdischarge Clinical Outcomes among Patients Hospitalized with Staphylococcus aureus Skin Infections
Samantha J. Eells et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Optimizing the Clinical Use of Vancomycin
Rocio Alvarez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections
A. Russo et al.
CLINICAL MICROBIOLOGY AND INFECTION (2016)
Emergence of linezolid- and vancomycin-resistant Enterococcus faecium in a department for hematologic stem cell transplantation
M. Krull et al.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL (2016)
Susceptibility trends including emergence of linezolid resistance among coagulase-negative staphylococci and meticillin-resistant Staphylococcus aureus from invasive infections
Jean-Winoc Decousser et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2015)
Staphylococcus aureus Bacteremia at 5 US Academic Medical Centers, 2008-2011: Significant Geographic Variation in Community-Onset Infections
Michael Z. David et al.
CLINICAL INFECTIOUS DISEASES (2014)
Executive Summary: Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
Dennis L. Stevens et al.
CLINICAL INFECTIOUS DISEASES (2014)
Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection
Helen W. Boucher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Eosinophilic Pneumonia in Patients Treated with Daptomycin Review of the Literature and US FDA Adverse Event Reporting System Reports
Peter W. Kim et al.
DRUG SAFETY (2012)
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children
Catherine Liu et al.
CLINICAL INFECTIOUS DISEASES (2011)
Why is community-associated MRSA spreading across the world and how will it change clinical practice?
Matteo Bassetti et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus
Daniel J. Pallin et al.
ANNALS OF EMERGENCY MEDICINE (2008)
Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections
LE Jauregui et al.
CLINICAL INFECTIOUS DISEASES (2005)
Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide
MB Dorr et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers
A Leighton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Causal relationship between neuropathy and prolonged linezolid use
F Frippiat et al.
CLINICAL INFECTIOUS DISEASES (2004)
Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections
E Seltzer et al.
CLINICAL INFECTIOUS DISEASES (2003)
分享论文
